###begin article-title 0
FimH Adhesin of Type 1 Fimbriae Is a Potent Inducer of Innate Antimicrobial Responses Which Requires TLR4 and Type 1 Interferon Signalling
###end article-title 0
###begin p 1
Conceived and designed the experiments: AAA. Performed the experiments: AAA KLM BKC RM. Analyzed the data: AAA KLM BKC. Contributed reagents/materials/analysis tools: CLG. Wrote the paper: AAA.
###end p 1
###begin p 2
###xml 266 274 266 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 279 286 279 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 540 543 537 540 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 549 552 546 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 569 572 559 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 580 583 570 573 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 674 677 664 667 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 694 697 677 680 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 703 706 686 689 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 714 717 697 700 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1041 1048 1013 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 1250 1253 1222 1225 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 361 367 <span type="species:ncbi:10090">murine</span>
###xml 584 588 <span type="species:ncbi:10090">mice</span>
###xml 718 722 <span type="species:ncbi:10090">mice</span>
###xml 1041 1048 <span type="species:ncbi:562">E. coli</span>
###xml 1050 1054 <span type="species:ncbi:562">UPEC</span>
###xml 1130 1134 <span type="species:ncbi:10090">mice</span>
###xml 1154 1158 <span type="species:ncbi:10090">mice</span>
###xml 1166 1170 <span type="species:ncbi:562">UPEC</span>
###xml 1254 1258 <span type="species:ncbi:10090">mice</span>
###xml 1391 1395 <span type="species:ncbi:562">UPEC</span>
Components of bacteria have been shown to induce innate antiviral immunity via Toll-like receptors (TLRs). We have recently shown that FimH, the adhesin portion of type 1 fimbria, can induce the innate immune system via TLR4. Here we report that FimH induces potent in vitro and in vivo innate antimicrobial responses. FimH induced an innate antiviral state in murine macrophage and primary MEFs which was correlated with IFN-beta production. Moreover, FimH induced the innate antiviral responses in cells from wild type, but not from MyD88-/-, Trif-/-, IFN-alpha/betaR-/- or IRF3-/- mice. Vaginal delivery of FimH, but not LPS, completely protected wild type, but not MyD88-/-, IFN-alpha/betaR-/-, IRF3-/- or TLR4-/- mice from subsequent genital HSV-2 challenge. The FimH-induced innate antiviral immunity correlated with the production of IFN-beta, but not IFN-alpha or IFN-gamma. To examine whether FimH plays a role in innate immune induction in the context of a natural infection, the innate immune responses to wild type uropathogenic E. coli (UPEC) and a FimH null mutant were examined in the urinary tract of C57Bl/6 (B6) mice and TLR4-deficient mice. While UPEC expressing FimH induced a robust polymorphonuclear response in B6, but not TLR4-/- mice, mutant bacteria lacking FimH did not. In addition, the presence of TLR4 was essential for innate control of and protection against UPEC. Our results demonstrate that FimH is a potent inducer of innate antimicrobial responses and signals differently, from that of LPS, via TLR4 at mucosal surfaces. Our studies suggest that FimH can potentially be used as an innate microbicide against mucosal pathogens.
###end p 2
###begin title 3
Author Summary
###end title 3
###begin p 4
###xml 463 470 463 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 716 723 716 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 463 470 <span type="species:ncbi:562">E. coli</span>
###xml 716 723 <span type="species:ncbi:562">E. coli</span>
The innate immune system is an evolutionarily conserved defence mechanism that protects the host from infection by microbes such as viruses, bacteria and fungi. Incoming pathogens are recognized by a set of evolutionary conserved receptors, including the Toll-like receptors (TLRs), that can be found on the surface of epithelial cells at the mucosal surface. We recently found that FimH, a specific adhesin located at the tip of type 1 fimbriae in uropathogenic E. coli, binds directly to TLR4. Here, we demonstrate the biological significance of this interaction. In the context of a natural infection, recognition of FimH by TLR4 is important for the host to mount an innate immune response against uropathogenic E. coli. Furthermore, we show that purified FimH protein induces a potent innate antiviral response, both in tissue culture and in animal models. This response is mediated predominantly by the production of type I interferon. Our results suggest that FimH is an excellent candidate for development as a microbicide against pathogen infection.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 96 99 96 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Biron1">[1]</xref>
###xml 100 103 100 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Biron2">[2]</xref>
###xml 104 107 104 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Ashkar1">[3]</xref>
###xml 108 111 108 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Duerst1">[4]</xref>
###xml 112 115 112 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Fawaz1">[5]</xref>
###xml 116 119 116 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Matsuo1">[6]</xref>
###xml 355 358 348 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Akira1">[7]</xref>
###xml 556 559 549 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Alexopoulou1">[8]</xref>
###xml 560 563 553 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Medzhitov1">[9]</xref>
###xml 564 568 557 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Medzhitov2">[10]</xref>
###xml 569 573 562 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Janeway1">[11]</xref>
###xml 574 578 567 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Alexopoulou2">[12]</xref>
###xml 638 642 631 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Ashkar2">[13]</xref>
###xml 643 647 636 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Chuang1">[14]</xref>
###xml 648 652 641 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Yarovinsky1">[15]</xref>
###xml 653 657 646 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Zhang1">[16]</xref>
###xml 712 716 705 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Akira2">[17]</xref>
###xml 717 721 710 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Akazawa1">[18]</xref>
###xml 622 626 <span type="species:ncbi:10090">mice</span>
###xml 631 637 <span type="species:ncbi:9606">humans</span>
The innate immune system plays a crucial role in the early defence against microbial infections [1],[2],[3],[4],[5],[6]. A key aspect of the innate immune response is the synthesis and secretion of type I interferons (IFN) such as IFN-alpha and IFN-beta. The innate immune system detects infections through germ-line encoded pattern recognition receptors [7], such as Toll-like receptors (TLRs). TLRs recognize conserved structures present in large groups of microorganisms, but not found in the host, called pathogen-associated molecular patterns (PAMPs) [8],[9],[10],[11],[12]. Thus far, 10 TLRs have been identified in mice and humans [13],[14],[15],[16], with each receptor recognizing a unique set of PAMPs [17],[18]. Examples of PAMPs include lipopolysaccharide (LPS, a ligand for TLR4), flagellin (a ligand for TLR5), double-stranded RNA (dsRNA, a ligand for TLR3), bacterial CpG DNA (a ligand for TLR9) and profillin (a ligand for TLR11). Upon ligand binding, TLRs initiate intracellular signalling through their cytoplasmic Toll/IL-1 (TIR) domain. These signalling pathways can be divided into common (MyD88-dependent) and specific (MyD88-independent) categories. TLR2, 5, 7-9 and 11 signalling is mainly MyD88-dependent, while TLR3 and 4 signalling is mediated through either MyD88 or Trif.
###end p 6
###begin p 7
###xml 170 177 170 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 182 190 182 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 190 193 190 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Ashkar1">[3]</xref>
###xml 194 198 194 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Ashkar3">[19]</xref>
###xml 199 203 199 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Harandi1">[20]</xref>
###xml 204 208 204 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Pyles1">[21]</xref>
###xml 209 213 209 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Sajic1">[22]</xref>
###xml 214 218 214 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Bellocchio1">[23]</xref>
###xml 907 911 885 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Shen1">[24]</xref>
###xml 623 627 <span type="species:ncbi:10090">mice</span>
###xml 773 777 <span type="species:ncbi:10090">mice</span>
Recently, we and others have reported that CpG ODN/TLR9 signalling leads to the induction of potent innate protection against herpes simplex virus (HSV-2) infection both in vivo and in vitro[3],[19],[20],[21],[22],[23]. Local intravaginal (IVAG) delivery of CpG ODN or Poly I:C resulted in rapid proliferation and thickening of the vaginal epithelium and induction of a innate antiviral state that did not block virus entry but inhibited viral replication in vaginal epithelial cells. This TLR ligand-induced innate protection correlated with production of IFN-beta, but not IFN-alpha, IFN-gamma or TNF-alpha. Treatment of mice lacking the IFN-alpha/betaR with CpG or Poly I:C did not provide innate antiviral protection against genital HSV-2 challenge compared to control mice. More recently, it has been shown that DC-derived IFNs are crucial for the innate antiviral activity of CpG in the genital tract [24].
###end p 7
###begin p 8
###xml 139 143 139 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Akazawa1">[18]</xref>
###xml 208 226 208 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Enterobacteriaceae</italic>
###xml 251 258 251 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 344 348 344 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Wizemann1">[25]</xref>
###xml 349 353 349 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Connell1">[26]</xref>
###xml 354 358 354 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Abraham1">[27]</xref>
###xml 450 454 450 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Wizemann1">[25]</xref>
###xml 455 459 455 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Vandemaele1">[28]</xref>
###xml 460 464 460 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Meiland1">[29]</xref>
###xml 465 469 465 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Hoepelman1">[30]</xref>
###xml 470 474 470 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Barnhart1">[31]</xref>
###xml 475 479 475 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Palaszynski1">[32]</xref>
###xml 480 484 480 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Langermann1">[33]</xref>
###xml 590 594 590 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Connell1">[26]</xref>
###xml 595 599 595 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Meiland1">[29]</xref>
###xml 600 604 600 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Martinez1">[34]</xref>
###xml 605 609 605 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Sokurenko1">[35]</xref>
###xml 610 614 610 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Jones1">[36]</xref>
###xml 755 759 755 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Mossman1">[37]</xref>
###xml 939 947 939 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 952 959 952 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 251 258 <span type="species:ncbi:562">E. coli</span>
###xml 443 449 <span type="species:ncbi:9606">humans</span>
###xml 741 747 <span type="species:ncbi:10090">murine</span>
Several PAMPs of bacterial origin including LPS, flagellin, peptidoglycan and bacterial DNA can activate the innate immune system via TLRs [18]. FimH, the adhesion portion of type 1 fimbriae produced by most Enterobacteriaceae including uropathogenic E. coli, is a conserved protein involved in bacterial attachment to mucosal epithelial cells [25],[26],[27]. Type I fimbriae have long been implicated in bacterial urinary tract infections in humans [25],[28],[29],[30],[31],[32],[33] and have been the focus of many attempts to generate a vaccine against pathogenic Gram-negative bacteria [26],[29],[34],[35],[36]. We have recently shown that recombinant FimH protein can activate the innate immune system through MyD88 and TLR4 in primary murine cells ([37] and un-published data). Little is known about the antiviral or antibacterial activity of FimH. Here we report that FimH is a potent inducer of innate antimicrobial responses. Our in vitro and in vivo experiments clearly show that FimH-induced innate antiviral immunity is associated with IFN-beta production and requires MyD88, Trif, TLR4, IRF-3 and type I IFN signalling.
###end p 8
###begin title 9
Results
###end title 9
###begin title 10
FimH induces potent innate antiviral immunity against HSV-2 infection in RAW264.7 cells
###end title 10
###begin p 11
###xml 241 245 237 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Mossman1">[37]</xref>
###xml 459 463 455 459 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig.</bold>
###xml 463 467 459 463 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1A&amp;B</bold>
###xml 459 467 455 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g001"><bold>Fig.</bold><bold>1A&amp;B</bold></xref>
###xml 569 576 554 561 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 1C</bold>
###xml 569 576 554 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g001"><bold>Fig. 1C</bold></xref>
###xml 639 643 624 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Dogan1">[38]</xref>
###xml 644 648 629 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Kisiela1">[39]</xref>
###xml 649 653 634 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Lindhorst1">[40]</xref>
###xml 654 658 639 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Kjaergaard1">[41]</xref>
###xml 836 840 821 825 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig.</bold>
###xml 840 842 825 827 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1D</bold>
###xml 836 842 821 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g001"><bold>Fig.</bold><bold>1D</bold></xref>
We have previously reported that bacterial LPS and CpG DNA as well as Poly I:C can induce innate antiviral responses in RAW264.7 cells. More recently, we have shown that FimH can stimulate these cells and induce the production of TNF-alpha ([37] and un-published data). Here we first examined if FimH-mediated signalling resulted in antiviral activity. RAW264.7 cells treated with FimH had significantly lower HSV-2 titers compared to cells treated with PBS (Fig.1A&B). This innate protection correlated with the production of IFN-beta, but not IFN-alpha or IFN-gamma (Fig. 1C). It is well documented that FimH binds to alpha-D-mannosides [38],[39],[40],[41]. We then examined if the mannose binding domain of FimH is involved in the signaling. Incubation of FimH with D-mannose had no effect on FimH-induced innate antiviral response (Fig.1D).
###end p 11
###begin title 12
Treatment of RAW264.7 cells with FimH induces the production of IFN-beta and significantly reduces HSV-2 replication.
###end title 12
###begin p 13
RAW264.7 cells were treated with either recombinant FimH (10 microg/mL), Poly I:C (10 microg/mL) or left untreated. Twenty-four hours post treatment cells were infected with HSV-2 with MOI of 0.1. Twenty hours post infection cells and the supernatant were collected and after 3 freeze/thaw cycles titered on Vero cells (A). Both FimH and Poly I:C treated cells had HSV-2 titers that were at least 2-3 logs lower compared to un-treated cells (A and B). Supernatants of treated cells were tested for IFN-alpha, IFN-beta and IFN-gamma (C). When FimH was incubated with alpha-D-Mannose (a standard blocker of binding to mannose) and then added to RAW264.7 cells, there was no inhibition of FimH innate antiviral activity (D).
###end p 13
###begin title 14
###xml 96 99 96 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 105 108 105 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 125 128 118 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 137 140 130 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 141 145 <span type="species:ncbi:10090">mice</span>
FimH induces strong innate antiviral responses (type I IFNs) in MEFs from B6, but not from MyD88-/-, Trif-/-, IFN-alpha/betaR-/- or IRF-3-/- mice
###end title 14
###begin p 15
###xml 98 102 98 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Mossman1">[37]</xref>
###xml 520 527 513 520 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 2A</bold>
###xml 520 527 513 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g002"><bold>Fig. 2A</bold></xref>
###xml 585 592 578 585 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 2B</bold>
###xml 585 592 578 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g002"><bold>Fig. 2B</bold></xref>
###xml 592 594 585 587 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&amp; </bold>
###xml 594 595 587 588 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</bold>
###xml 594 595 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g003"><bold>3</bold></xref>
###xml 736 743 729 736 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 3A</bold>
###xml 736 743 729 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g003"><bold>Fig. 3A</bold></xref>
###xml 1082 1089 1075 1082 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 2B</bold>
###xml 1082 1089 1075 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g002"><bold>Fig. 2B</bold></xref>
###xml 1089 1091 1082 1084 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">, </bold>
###xml 1091 1095 1084 1088 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3B,C</bold>
###xml 1091 1095 1084 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g003"><bold>3B,C</bold></xref>
###xml 1247 1250 1230 1233 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1259 1262 1242 1245 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1438 1445 1421 1428 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 2B</bold>
###xml 1438 1445 1421 1428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g002"><bold>Fig. 2B</bold></xref>
###xml 1445 1446 1428 1429 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">,</bold>
###xml 1446 1450 1429 1433 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3D,E</bold>
###xml 1446 1450 1429 1433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g003"><bold>3D,E</bold></xref>
###xml 1642 1646 1625 1629 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig.</bold>
###xml 1646 1650 1629 1633 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2A,B</bold>
###xml 1642 1650 1625 1633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g002"><bold>Fig.</bold><bold>2A,B</bold></xref>
###xml 1650 1651 1633 1634 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">,</bold>
###xml 1651 1655 1634 1638 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3D,E</bold>
###xml 1651 1655 1634 1638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g003"><bold>3D,E</bold></xref>
###xml 79 85 <span type="species:ncbi:10090">murine</span>
###xml 178 183 <span type="species:ncbi:10090">mouse</span>
###xml 1263 1267 <span type="species:ncbi:10090">mice</span>
Recently we have shown that FimH signalling required TLR4 and MyD88 pathway in murine macrophages [37]. It is well documented that Poly I:C induces strong antiviral responses in mouse embryonic fibroblasts (MEFs) as measured by a standard VSV plaque reduction assay. We first examined whether FimH could induce the production of type 1 IFNs, resulting in an innate antiviral state in B6 MEFs. Interestingly, FimH induced similar levels of IFN-beta, but not IFN-alpha, in B6 MEFs compared to those treated with Poly I:C (Fig. 2A) and provided complete protection against VSV challenge (Fig. 2B& 3). B6 MEFs treated with FimH also showed little or no VSV-GFP replication, as detected by GFP fluorescence, when compared to untreated MEFs (Fig. 3A). We then examined whether FimH-induced innate antiviral responses were MyD88, Trif and/or type I IFN dependent. FimH failed to provide protection against VSV challenge in MEFs deficient in either the MyD88 or Trif adaptors, whereas Poly I:C provided complete protection in MEFs lacking MyD88 and partial protection in MEFs lacking Trif (Fig. 2B, 3B,C). To further investigate whether type 1 IFNs, particularly IFN-beta, were involved in FimH-induced innate antiviral immunity, MEFs from IFN-alpha/betaR-/- or IRF-3-/- mice were treated with FimH or Poly I:C and then challenged with VSV. FimH failed to induce an innate antiviral state in the absence of either IRF-3 or type 1 IFN signalling (Fig. 2B,3D,E). Poly I:C induced only moderate protection at 30 nM or 15 nM, but no significant differences in VSV-GFP fluorescence was observed in MEFs at lower concentrations compared to untreated MEFs (Fig.2A,B,3D,E).
###end p 15
###begin title 16
###xml 67 70 67 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 76 79 76 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 86 89 86 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 109 112 102 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
FimH induces strong innate antiviral responses in B6, but not MyD88-/-, Trif-/-, IRF-3-/- or IFN-Ralpha/beta -/-MEFs.
###end title 16
###begin p 17
###xml 376 379 354 357 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 386 389 364 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 395 398 373 376 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 416 419 387 390 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 839 840 790 791 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1490 1493 1429 1432 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1499 1502 1438 1441 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1519 1522 1451 1454 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1531 1534 1463 1466 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
B6 MEFs were split at passage 3 and then treated with either FimH (10 microg/ml), Poly I:C (10 microg/ml) or left untreated for 24 hours. The supernatants were removed and were used to measure levels of IFN-alpha and IFN-beta. Both FimH and Poly I:C treatment induced significant levels of IFN-beta, but not IFN-alpha, in B6 MEFs (A). In a next series of experiments B6, IRF-3-/-, MyD88-/-, Trif-/- or IFNalpha/betaR-/- MEFs, at passage three, were seeded into 12-well plates, 24 hours prior to treatment. Serial dilutions of Poly I:C or FimH were made in complete 10% alpha-MEM media, then 500 microl were added directly to the MEFs and cells were allowed to incubate at 37degreesC for 24 hours. Twenty-four hours post treatment the supernatants were aspirated and stored at -20degreesC for future use. Then 200 microl of VSV-GFP (3.18x104 pfu/ml) in 0% alpha-MEM were added to each well and then cells were incubated for 1 hour at 37degreesC with rocking every 10 minutes. After 1 hour, VSV-GFP inoculums were aspirated from each well and cells were overlayed with 1 ml of 10% alpha-MEM /1% methylcellulose and incubated for 24 hours at 37degreesC. After 24 hours, VSV-GFP plaques were visualized using a Typhoon phosphoimager. (B) Represents photomicrographs of GFP expression in MEFs treated with FimH, Poly I;C or un-treated controls. In B6 MEFs FimH as well as Poly I:C treatment provide complete protection against VSV compared to controls. FimH failed to provide protection in MyD88-/-, Trif-/- , IFNalpha/betaR-/- or IRF-3-/- MEFs.
###end p 17
###begin title 18
###xml 67 70 67 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 76 79 76 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 86 89 86 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 109 112 102 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
FimH induces strong innate antiviral responses in B6, but not MyD88-/-, Trif-/-, IRF-3-/- or IFN-Ralpha/beta -/-MEFs.
###end title 18
###begin p 19
###xml 0 8 0 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g003">Figure 3</xref>
###xml 386 389 386 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 395 398 395 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 414 417 407 410 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 427 430 420 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 631 634 624 627 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 648 651 641 644 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 667 670 653 656 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 679 682 665 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
Figure 3 shows mean GFP florescent intensity of MEFs treated with different concentrations of FimH or Poly I:C relative to untreated VSV-GFP infected cells (RFU). Values from control un-infected wells were used as background. Values from infected, untreated, wells (positive controls) were set at 100%. B6 MEFs treated with FimH or Poly I:C had significantly lower infections (A). MyD88-/-, Trif-/-, IFNalpha/betaR-/- and IRF-3-/- MEFs treated with FimH showed no significant reduction in relative GFP fluorescence compared to untreated positive controls (B-E). Poly I:C treatment provided complete protection against VSV in My D88-/-, but not Trif-/-, IFNalpha/betaR-/- or IRF-3-/- MEFs.
###end p 19
###begin title 20
###xml 70 74 <span type="species:ncbi:10090">mice</span>
Vaginal delivery of recombinant FimH, but not LPS, protects normal B6 mice from subsequent IVAG HSV-2 challenge
###end title 20
###begin p 21
###xml 181 184 181 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Ashkar1">[3]</xref>
###xml 185 189 185 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Ashkar3">[19]</xref>
###xml 190 194 190 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Sajic1">[22]</xref>
###xml 526 530 526 530 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig.</bold>
###xml 530 532 530 532 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4A</bold>
###xml 526 532 526 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g004"><bold>Fig.</bold><bold>4A</bold></xref>
###xml 655 659 655 659 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig.</bold>
###xml 659 661 659 661 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4B</bold>
###xml 655 661 655 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g004"><bold>Fig.</bold><bold>4B</bold></xref>
###xml 344 348 <span type="species:ncbi:10090">mice</span>
###xml 358 362 <span type="species:ncbi:10090">mice</span>
###xml 520 524 <span type="species:ncbi:10090">mice</span>
###xml 624 628 <span type="species:ncbi:10090">mice</span>
###xml 649 653 <span type="species:ncbi:10090">mice</span>
We have reported that the mucosal delivery of some TLR ligands/agonists can induce an innate antiviral state and provide complete protection against subsequent IVAG HSV-2 challenge [3],[19],[22]. To examine if local delivery of FimH can provide innate protection against subsequent IVAG HSV-2 challenge, FimH was administered intravaginally to mice and then mice were challenged with lethal doses of HSV-2 24 hours following this treatment. FimH provided 100% protection against IVAG HSV-2 challenge compared to control mice (Fig.4A). Moreover, HSV-2 virus particles were not present in the vaginal washes from FimH-treated mice compared to control mice (Fig.4B).
###end p 21
###begin title 22
Local delivery of FimH induces potent innate antiviral immunity against IVAG HSV-2 challenge.
###end title 22
###begin p 23
###xml 255 256 255 256 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 26 30 <span type="species:ncbi:10090">mice</span>
###xml 116 120 <span type="species:ncbi:10090">mice</span>
###xml 198 202 <span type="species:ncbi:10090">mice</span>
###xml 274 278 <span type="species:ncbi:10090">mice</span>
###xml 358 362 <span type="species:ncbi:10090">Mice</span>
###xml 509 513 <span type="species:ncbi:10090">mice</span>
Six- to eight-week-old B6 mice were treated with Depo-Provera to synchronize their susceptibility. Four days later, mice were treated locally with FimH or Poly I:C. Twenty-four hours post treatment mice were challenged IVAG with a lethal dose of HSV-2 (104 pfu). Challenged mice were monitored daily for genital pathology, survival and vaginal virus titers. Mice that received FimH or Poly I:C were protected against IVAG HSV-2 challenge (A) and showed no HSV-2 titers in the genital washes compared to naive mice (B).
###end p 23
###begin p 24
###xml 574 583 574 583 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5A</bold>
###xml 574 583 574 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g005"><bold>Figure 5A</bold></xref>
###xml 752 759 752 759 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 5B</bold>
###xml 752 759 752 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g005"><bold>Fig. 5B</bold></xref>
###xml 1058 1065 1058 1065 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 5C</bold>
###xml 1058 1065 1058 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g005"><bold>Fig. 5C</bold></xref>
###xml 71 75 <span type="species:ncbi:10090">mice</span>
###xml 203 207 <span type="species:ncbi:10090">mice</span>
###xml 276 280 <span type="species:ncbi:10090">mice</span>
###xml 415 419 <span type="species:ncbi:10090">mice</span>
###xml 624 628 <span type="species:ncbi:10090">mice</span>
###xml 675 679 <span type="species:ncbi:10090">Mice</span>
To further verify that the innate antiviral protection in FimH-treated mice was due to the direct effects of FimH protein, but not LPS or other bacterial contaminants, we performed three experiments: 1) mice were treated with 5000 ng of LPS and then challenged with HSV-2; 2) mice were treated with protease-digested FimH (complete digestion was confirmed by gel electrophoresis) and then challenged with HSV-2; 3) mice were treated with either FimH or another component of bacterial pilin (PapG), which were expressed, purified and prepared in the same manner. As shown in Figure 5A neither LPS nor digested FimH protected mice against subsequent challenge with IVAG HSV-2. Mice treated with PapG were also not protected against IVAG HSV-2 challenge (Fig. 5B). However, both FimH and PapG were prepared identically and the preparations had similar levels of LPS. Interestingly, FimH, but not LPS, induced dramatic morphological changes in the genital mucosa, including thickening of the vaginal epithelium and recruitment of polymorphonuclear cells (PMNs) (Fig. 5C).
###end p 24
###begin title 25
Induction of innate antiviral immunity by FimH at the genital mucosa is independent of LPS or other bacterial contaminants.
###end title 25
###begin p 26
###xml 408 409 408 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 781 790 737 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g005">Figure 5C</xref>
###xml 44 48 <span type="species:ncbi:10090">mice</span>
###xml 158 162 <span type="species:ncbi:10090">mice</span>
###xml 265 269 <span type="species:ncbi:10090">mice</span>
###xml 351 355 <span type="species:ncbi:10090">mice</span>
###xml 427 431 <span type="species:ncbi:10090">mice</span>
###xml 514 518 <span type="species:ncbi:10090">Mice</span>
###xml 682 686 <span type="species:ncbi:10090">mice</span>
###xml 701 705 <span type="species:ncbi:10090">mice</span>
Six- to eight-week-old B6 (N = 5 per group) mice were treated with Depo-Provera to synchronize their susceptibility to IVAG HSV-2 challenge. Four days later, mice were treated locally with intact FimH, digested and/or head-inactivated FimH or LPS. Another group of mice were treated with FimH, PapG or left untreated. Twenty-four hours post treatment mice were challenged IVAG with a lethal dose of HSV-2 (104 pfu). Challenged mice were monitored daily for genital pathology, survival and vaginal virus titer. (A) Mice that received FimH (*) were protected against IVAG HSV-2 challenge compared to digested FimH (black triangle), LPS (blacksquare, square, filled) or naive (square) mice. Treatment of mice with PaPG did not provide any protection against IVAG HSV-2 challenge (B). Figure 5C shows photomicrograph of vaginal tissue cut in cross section and stained with H&E.
###end p 26
###begin title 27
MyD88 and IFN-beta signalling as well as TLR4 are required for FimH-induced innate protection against genital HSV-2 infection
###end title 27
###begin p 28
###xml 4 12 4 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 401 404 401 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 411 418 411 418 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 6A</bold>
###xml 411 418 411 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g006"><bold>Fig. 6A</bold></xref>
###xml 537 544 534 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 602 605 592 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 615 618 605 608 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 702 706 692 696 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig.</bold>
###xml 706 708 696 698 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6A</bold>
###xml 702 708 692 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g006"><bold>Fig.</bold><bold>6A</bold></xref>
###xml 836 843 819 826 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 6B</bold>
###xml 836 843 819 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g006"><bold>Fig. 6B</bold></xref>
###xml 1035 1044 1010 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000233.s001">Figure S1</xref>
###xml 1106 1109 1081 1084 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1202 1205 1177 1180 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1277 1284 1252 1259 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 6C</bold>
###xml 1277 1284 1252 1259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g006"><bold>Fig. 6C</bold></xref>
###xml 201 205 <span type="species:ncbi:10090">mice</span>
###xml 321 325 <span type="species:ncbi:10090">mice</span>
###xml 405 409 <span type="species:ncbi:10090">mice</span>
###xml 619 623 <span type="species:ncbi:10090">mice</span>
###xml 696 700 <span type="species:ncbi:10090">mice</span>
###xml 1110 1114 <span type="species:ncbi:10090">mice</span>
###xml 1206 1210 <span type="species:ncbi:10090">mice</span>
###xml 1239 1243 <span type="species:ncbi:10090">mice</span>
Our in vitro observations show that FimH signalling requires TLR4, MyD88 and type 1 IFN signalling to induce innate antiviral activity. Thus, we examined whether vaginal delivery of FimH could protect mice lacking these innate factors against genital HSV-2 infection. While FimH provided nearly complete protection in B6 mice, there was no protection against IVAG HSV-2 challenge in FimH-treated MyD88-/- mice (Fig. 6A). We also examined if type I IFNs, particularly IFN-beta, were involved in the FimH-induced innate antiviral immunity in vivo. Vaginal delivery of FimH and Poly I:C to IFN-alpha/betaR-/- and IRF-3-/- mice failed to protect them against IVAG HSV-2 challenge compared to control mice (Fig.6A). This innate protection strongly correlated with the production of IFN-beta, but not IFN-alpha, levels in the vaginal washes (Fig. 6B). To ensure that the ELISA kit could detect naturally produced IFN-alpha, we used supernatants from BM-DCs treated with Poly I:C or CpG ODN and were able to detect high levels of mIFN-alpha (Figure S1). Finally, to confirm that FimH signals via TLR4, B6 and TLR4-/- mice were treated with FimH and then challenged with IVAG HSV-2. FimH failed to protect TLR4-/- mice but completely protected B6 mice against genital HSV-2 challenge (Fig. 6C).
###end p 28
###begin title 29
TLR4 and Type 1 IFN signalling, particularly IFN-beta, are required for FimH-induced innate protection against HSV-2 challenge.
###end title 29
###begin p 30
###xml 39 42 39 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 49 52 49 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 70 73 63 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 285 286 274 275 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 525 528 514 517 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 561 564 530 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 603 606 546 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 738 741 672 675 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 789 792 723 726 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1022 1025 945 948 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1142 1145 1062 1065 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1325 1328 1245 1248 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 123 127 <span type="species:ncbi:10090">mice</span>
###xml 169 174 <span type="species:ncbi:10090">mouse</span>
###xml 228 232 <span type="species:ncbi:10090">mice</span>
###xml 304 308 <span type="species:ncbi:10090">mice</span>
###xml 400 404 <span type="species:ncbi:10090">mice</span>
###xml 617 621 <span type="species:ncbi:10090">mice</span>
###xml 742 746 <span type="species:ncbi:10090">mice</span>
###xml 793 797 <span type="species:ncbi:10090">mice</span>
###xml 839 844 <span type="species:ncbi:10090">mouse</span>
###xml 1026 1030 <span type="species:ncbi:10090">mice</span>
###xml 1133 1137 <span type="species:ncbi:10090">mice</span>
###xml 1146 1150 <span type="species:ncbi:10090">mice</span>
###xml 1329 1333 <span type="species:ncbi:10090">mice</span>
Six- to eight-week-old female B6, IRF-3-/-, MyD88-/- or IFNalpha/betaR-/- were treated with Depo-Provera. Four days later, mice were treated with either FimH (40 microg/mouse) or left untreated. Twenty-four hours post treatment mice were challenged with a lethal dose IVAG of HSV-2 (104 pfu). Challenged mice were monitored daily for genital pathology, survival and vaginal virus titers. (A) Only B6 mice that received FimH (*) showed 90% protection against IVAG HSV-2 challenge compared to naive B6 (o) or FimH treated MyD88-/- (black triangle), IFNalpha/betaR-/- (blacksquare, square, filled) or IRF-3-/- (diamond) mice. Figure 11b shows that local delivery of FimH induces production of significant levels IFN-beta in B6, but not MyD88-/- mice. Six- to eight-week-old female B6 or MyD88-/- mice were treated with either FimH (40 microg/mouse) or left untreated. (B) Vaginal washes were collected at 12 and 24 hours post treatment and were used to measure levels of IFN-beta and IFN-alpha using ELISA. Treatment of MyD88-/- mice induced significantly (p<0.001) lower levels of IFN-beta compared to B6 controls. (C) 6-8 week-old B6 mice TLR4-/- mice were treated with FimH and then challenged with IVAG HSV-2 as described above. Local delivery of FimH failed to provide innate protection against IVAG HSV-2 challenge in TLR4-/- mice.
###end p 30
###begin title 31
TLR4 is essential for innate response to FimH-expressing bacteria
###end title 31
###begin p 32
###xml 67 74 67 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 82 86 82 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Connell1">[26]</xref>
###xml 457 464 457 464 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 7A</bold>
###xml 457 464 457 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g007"><bold>Fig. 7A</bold></xref>
###xml 573 580 573 580 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 7B</bold>
###xml 573 580 573 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g007"><bold>Fig. 7B</bold></xref>
###xml 720 723 720 723 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 822 829 810 817 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 7C</bold>
###xml 822 829 810 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000233-g007"><bold>Fig. 7C</bold></xref>
###xml 891 894 879 882 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1012 1015 1000 1003 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1105 1109 1093 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Langermann1">[33]</xref>
###xml 67 74 <span type="species:ncbi:562">E. coli</span>
###xml 76 80 <span type="species:ncbi:562">UPEC</span>
###xml 256 260 <span type="species:ncbi:10090">mice</span>
###xml 280 284 <span type="species:ncbi:10090">mice</span>
###xml 320 324 <span type="species:ncbi:562">UPEC</span>
###xml 355 359 <span type="species:ncbi:10090">mice</span>
###xml 361 365 <span type="species:ncbi:562">UPEC</span>
###xml 567 571 <span type="species:ncbi:10090">mice</span>
###xml 724 728 <span type="species:ncbi:10090">mice</span>
###xml 816 820 <span type="species:ncbi:10090">mice</span>
###xml 895 899 <span type="species:ncbi:10090">mice</span>
###xml 1072 1076 <span type="species:ncbi:562">UPEC</span>
###xml 1212 1216 <span type="species:ncbi:10090">mice</span>
FimH plays an important role in the pathogenicity of uropathogenic E. coli (UPEC) [26]. To examine whether FimH plays a role in innate immune induction in the context of a natural infection, we measured PMN leukocyte recruitment to the urinary tract in B6 mice and TLR4-deficient mice following infection with wild type UPEC and a fimH null mutant. In B6 mice, UPEC expressing FimH induced a rapid PMN response whereas mutant bacteria lacking FimH did not (Fig. 7A). This FimH-induced PMN influx required TLR4, since the cellular influx was blocked in TLR4-deficient mice (Fig. 7B). The bacterial load was enumerated in the bladder 24 h after infection. TLR4 was required for control of infection in the bladder, as TLR4-/- mice had approximately1.5-log more wild type bacteria in the bladder at 24 h compared to B6 mice (Fig. 7C), which correlated with a loss of PMN recruitment in the TLR4-/- mice. Deletion of fimH resulted in decreased colonization of the bladder but this decrease was not overcome in a TLR4-/- background, confirming that while FimH is important for UPEC colonization of the bladder [33], FimH-independent signaling through TLR4 is not likely a major contributor to infection control in B6 mice.
###end p 32
###begin title 33
###xml 46 50 <span type="species:ncbi:562">UPEC</span>
TLR4 is required for innate response to FimH+ UPEC.
###end title 33
###begin p 34
###xml 67 70 67 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 158 159 158 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 526 529 526 529 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 578 579 578 579 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 574 579 574 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fimH<sup>&#8722;</sup></italic>
###xml 601 622 601 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 926 929 926 929 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 960 961 960 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 50 54 <span type="species:ncbi:562">UPEC</span>
###xml 78 82 <span type="species:ncbi:10090">mice</span>
###xml 183 187 <span type="species:ncbi:562">UPEC</span>
###xml 234 238 <span type="species:ncbi:10090">mice</span>
###xml 342 346 <span type="species:ncbi:10090">mice</span>
###xml 481 485 <span type="species:ncbi:562">UPEC</span>
###xml 530 534 <span type="species:ncbi:10090">mice</span>
###xml 580 584 <span type="species:ncbi:562">UPEC</span>
###xml 954 958 <span type="species:ncbi:562">UPEC</span>
(A) Polymorphonuclear response to FimH+ and FimH- UPEC. B6 and TLR4-/- female mice, aged 8-10 weeks, were used for the experiments. For infections, 0.1 ml (108 cfu) of FimH+ or FimH- UPEC was injected into the bladder of anesthetized mice using a soft catheter (0.7 mm) placed in the urethra. Urine was collected from uninfected and infected mice and the cfu was enumerated. (N = 5 per time point). Polymorphonuclear leukocytes in urine were quantified using a haemocytometer. (B) UPEC colonization of the bladder. B6 and TLR4-/- mice were infected with either wild type or fimH- UPEC as described in Materials and Methods. Twenty-four hours after infection, the bladders were removed, homogenized and the bacterial load was enumerated (C). Each data point represents one infected animal and data shown is from three independent experiments. Horizontal lines within each scatter of data represent the geometric mean. B6 vs TLR-/- infected with wild type UPEC (P<0.001, ANOVA); ns, not significant.
###end p 34
###begin title 35
Discussion
###end title 35
###begin p 36
###xml 85 92 85 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitr</italic>
###xml 98 105 98 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 156 159 156 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 165 168 165 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 175 178 175 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 197 200 190 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 417 420 410 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
###xml 201 205 <span type="species:ncbi:10090">mice</span>
###xml 362 366 <span type="species:ncbi:10090">mice</span>
###xml 421 425 <span type="species:ncbi:10090">mice</span>
###xml 727 733 <span type="species:ncbi:562">E.coli</span>
###xml 842 846 <span type="species:ncbi:562">UPEC</span>
We have demonstrated here that FimH can induce a potent innate antiviral state, both in vitro and in vivo. Pre-treatment of MEFs from B6 mice, but not MyD88-/-, Trif-/-, IRF-3-/- or IFN-alpha/betaR-/- mice, with FimH conferred protective antiviral responses. Mucosal delivery of FimH, but not LPS, provided complete protection against IVAG HSV-2 challenge in B6 mice while it failed to provide any protection in MyD88-/- mice. Moreover, the FimH-induced innate antiviral immunity was associated with the induction of IFN-beta in the genital tract and required TLR4 and IRF-3. To evaluate the biological significance of FimH in host pathogen interaction, we have examined the host innate response in FimH knockout uropathogenic E.coli in the presence and absence of TLR4. TLR4 was required for the induction of innate immune responses against UPEC.
###end p 36
###begin p 37
###xml 183 191 183 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 196 203 196 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 203 206 203 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Ashkar1">[3]</xref>
###xml 207 211 207 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Ashkar3">[19]</xref>
###xml 212 216 212 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Sajic1">[22]</xref>
###xml 611 615 588 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Liu1">[42]</xref>
###xml 729 732 703 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Biron1">[1]</xref>
###xml 733 736 707 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Biron2">[2]</xref>
###xml 737 741 711 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Benencia1">[43]</xref>
###xml 742 746 716 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Benencia2">[44]</xref>
###xml 747 751 721 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Biron3">[45]</xref>
###xml 60 66 <span type="species:ncbi:10090">murine</span>
We have shown that FimH requires TLR4 and MyD88 to activate murine primary macrophages. In addition we have also reported that dsRNA and CpG ODN confer protection against HSV-2, both in vitro and in vivo[3],[19],[22]. Similar to Poly I:C and CpG, the FimH-induced innate antiviral state correlates with IFN-beta, but not IFN-alpha or IFN-gamma production. Although we have observed high levels of TNF-alpha, it is unlikely that the FimH induced innate antiviral activity is mediated via TNF-alpha. Previous work showed that treatment of RAW264.7 cells with TNF-alpha cannot protect them against HSV-2 infection [42]. FimH also induces significant levels of NO production. Both IFN-beta and NO are able to block HSV-2 replication [1],[2],[43],[44],[45].
###end p 37
###begin p 38
###xml 365 372 362 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 998 1001 982 985 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 365 372 <span type="species:ncbi:562">E. coli</span>
We have observed induction of a strong innate antiviral state by FimH that correlated with the production of IFN-beta, and required TLR4. It was first important to establish whether, in addition to TLR4, FimH binding to its natural receptor, mannose, is essential for induction of innate antiviral activity. It is well documented that FimH adhesin of uropathogenic E. coli type 1 fimbriae bind to mannose on epithelial cells. Blocking the mannose-binding portion of FimH with D-mannose had no effect on the FimH-induced innate antiviral activity. This suggested that FimH may bind to TLR4 independent of mannose to induce antiviral responses. We were unable to detect any IFN-alpha from FimH treated RAW264.7 or B6 MEFS by ELISA. This suggested that IFN-beta is the key factor in the FimH-induced innate antiviral state. Given the importance of the transcription factor IRF3 in the production of IFN-beta in fibroblast and epithelial cells, FimH also failed to induce IFN-beta production from IRF-3-/- MEFs and did not protect these cells against VSV. Taken together, these data indicate that FimH signals through IRF3 in the induction of an innate antiviral response.
###end p 38
###begin p 39
###xml 115 118 115 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Ashkar1">[3]</xref>
###xml 119 123 119 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Ashkar3">[19]</xref>
###xml 124 128 124 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Harandi1">[20]</xref>
###xml 129 133 129 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Pyles1">[21]</xref>
###xml 134 138 134 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Sajic1">[22]</xref>
###xml 139 143 139 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Herbst1">[46]</xref>
###xml 318 322 311 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Gill1">[47]</xref>
###xml 411 414 404 407 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 421 424 414 417 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 440 443 426 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 452 455 438 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 621 624 604 607 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 672 675 652 655 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 70 74 <span type="species:ncbi:10090">mice</span>
###xml 456 460 <span type="species:ncbi:10090">mice</span>
###xml 625 629 <span type="species:ncbi:10090">mice</span>
###xml 676 680 <span type="species:ncbi:10090">mice</span>
###xml 704 708 <span type="species:ncbi:10090">mice</span>
We and others have shown that mucosal delivery of TLR ligands protect mice against subsequent IVAG HSV-2 challenge [3],[19],[20],[21],[22],[46]. More recently, we have found that the TLR ligand-induced innate antiviral responses against IVAG HSV-2 strongly correlate with the production of IFN-beta, but not IFN-alpha [47]. Our data show that FimH activity of FimH against genital HSV-2 challenge requires MyD88-/-, IRF-3-/- IFN-alpha/betaR-/- and TLR4-/- mice did not provide any protection against subsequent IVAG HSV-2 challenge compared to B6 control. FimH also induced significantly lower levels of IFN-beta in MyD88-/- mice while IFN-beta was not detectable in IRF-3-/- mice compared to B6 control mice. This clearly suggested that FimH-induced innate antiviral activity against IVAG HSV-2 is mediated via TLR4, MyD88 and type 1 IFNs, particularly IFN-beta.
###end p 39
###begin p 40
###xml 209 217 209 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 222 229 222 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 796 804 796 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 809 816 809 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 877 884 877 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1458 1466 1458 1466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1656 1660 1656 1660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Mossman1">[37]</xref>
###xml 1945 1949 1945 1949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Mossman1">[37]</xref>
###xml 1083 1087 <span type="species:ncbi:10090">mice</span>
###xml 1351 1355 <span type="species:ncbi:10090">mice</span>
###xml 1847 1851 <span type="species:ncbi:10090">mice</span>
Since we purified recombinant FimH from bacteria, it was essential to confirm that the antiviral activity seen with the purified FimH was not due to LPS contamination and/or other possible minor proteins. Our in vitro and in vivo data clearly showed that the antiviral activity of FimH was not due to contamination with LPS. We have used all possible controls to confirm that FimH was responsible for the innate antiviral responses. First, control samples from bacteria that contained empty vector and processed in exactly the same manner as FimH had no antiviral activity assuring that the antiviral response seen with FimH is not due to low levels of LPS contamination. Second, both enzymatic digestion and heat inactivation of FimH protein significantly abrogated the activity of FimH protein in vitro and in vivo. To also confirm that FimH, but not LPS, is responsible for in vivo innate antiviral responses, we performed several experiments. First; local delivery of LPS or digested/heat-inactivated FimH protein gave no protection against subsequent IVAG HSV-2 challenge in B6 mice compared to treatment with intact FimH protein. Second; local delivery of recombinant PapG protein, another adhesin of fimbriated bacteria which was prepared exactly with the same protocol as FimH, gave no protection against subsequent IVAG HSV-2 challenge in B6 mice compared to FimH. However, PapG protein had the same levels of LPS compared to FimH. In addition, our in vitro experiments clearly showed that low levels of LPS present in our samples cannot provide any protection against viral infections. In addition we have shown that FimH can directly bind TLR4 ([37] and un-published data). Furthermore, while FimH induced dramatic changes in genital mucosa, there was no difference in the histomorphology of the genital mucosa from LPS- or PBS-treated mice. More importantly, our recent data indicates that FimH signals in cells unresponsive to LPS ([37] and un-published data).
###end p 40
###begin p 41
###xml 456 457 456 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 614 621 614 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 621 625 621 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Fischer1">[48]</xref>
###xml 795 802 795 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 856 860 856 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fimH</italic>
###xml 934 938 934 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Langermann1">[33]</xref>
###xml 976 977 976 977 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 972 977 972 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fimH<sup>&#8722;</sup></italic>
###xml 1011 1014 1011 1014 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 129 133 <span type="species:ncbi:562">UPEC</span>
###xml 229 233 <span type="species:ncbi:562">UPEC</span>
###xml 308 312 <span type="species:ncbi:10090">mice</span>
###xml 458 462 <span type="species:ncbi:562">UPEC</span>
###xml 614 621 <span type="species:ncbi:562">E. coli</span>
###xml 641 645 <span type="species:ncbi:562">UPEC</span>
###xml 795 802 <span type="species:ncbi:562">E. coli</span>
###xml 978 982 <span type="species:ncbi:562">UPEC</span>
###xml 1152 1156 <span type="species:ncbi:10090">mice</span>
It is well known that FimH play an import role in attachment of bacteria to epithelial cells and contributes to pathogenecity of UPEC. Our data show that TLR4 is involved in FimH signalling with epithelial cells. FimH-expressing UPEC were able to induce recruitment of PMNs to the urinary tract of wild type mice, while isogenic bacteria lacking FimH did not. Interestingly, this response is controlled by TLR4 expression and is abolished when we used FimH- UPEC, even in the presence of TLR4. These data are similar to the PMN response seen following infection with a type I fimbriated derivative of non-adhesive E. coli[48]. Because these UPEC strains share expression of another TLR4-activating PAMP (LPS), these data suggest that the dominant innate immune-activating PAMP on uropathogengic E. coli may in fact be FimH. In support of this, deletion of fimH resulted in decreased colonization of the bladder as reported previously [33] but the level of colonization by fimH- UPEC was similar in a B6 and TLR4-/- background. These data suggest that FimH-independent signaling through TLR4 is not likely a major contributor to infection control in B6 mice.
###end p 41
###begin p 42
###xml 828 833 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
This is the first report to show that FimH has potent innate antiviral activity which also requires TLR4, MyD88, Trif, IRF-3 and type 1 IFNs, particularly IFN-beta. So far, TLR ligands such as dsRNA, ssRNA, and CpG DNA have been associated with the induction of innate antiviral immunity. Protein ligands of TLRs have not been associated with the induction of innate antiviral immunity. Here, however, we demonstrate that FimH, but not LPS, mediates innate antiviral activity at the genital mucosa. It is of particular interest that both TLR5 and TLR11 ligands signal via MyD88, whereas FimH protein signals through both MyD88 and Trif, leading to activation of the IRF-3 pathway. Results from this study may provide the basis for a novel mucosal innate microbicide for a vast variety of mucosal viral infections such as HSV-2, HIV-1 or other sexually transmitted infections.
###end p 42
###begin title 43
Materials and Methods
###end title 43
###begin title 44
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 44
###begin p 45
###xml 117 120 117 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 216 219 209 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 310 313 303 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 320 323 313 316 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 332 335 325 328 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 121 125 <span type="species:ncbi:10090">mice</span>
###xml 336 340 <span type="species:ncbi:10090">mice</span>
###xml 476 480 <span type="species:ncbi:10090">mice</span>
Female C57BL/6, 129SVPasCrl mice, 8-12 weeks old, were purchased from Charles River Laboratory (Quebec, Canada). TLR4-/- mice were purchased from Jackson laboratory (Bar Harbor, USA). Breeding pairs of IFNalpha/betaR-/- were kindly provided by Rolf M. Zinkernagel (Zurich, Switzerland). Breeding pairs of IRF-3-/-, MyD88-/- and Trif-/- mice were kindly provided by Dr. T. Taniguchi (via Dr. T. Moran), Dr. S. Akira (via Dr. D. Golenbock) and Dr. B. Beutler, respectively. All mice were housed in level B rooms which followed a 12 hour day and 12 hour night schedule, and were maintained under standard temperature controlled conditions.
###end p 45
###begin title 46
Cells, viruses and reagents
###end title 46
###begin p 47
###xml 86 89 86 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 96 99 96 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 105 108 105 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 127 130 120 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 567 571 552 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Docherty1">[49]</xref>
###xml 131 137 <span type="species:ncbi:10090">murine</span>
RAW264.7, HEL fibroblasts and BJ fibroblasts cells were purchased from ATCC. B6, IRF-3-/-, MyD88-/-, Trif-/- and IFNalpha/betaR-/- murine embryonic fibroblasts (MEFs) were prepared from gestation day 13.5 in alpha-MEM with 20% FBS and weaned then grown in 10% alpha-MEM for experiments. 293, 293-hTLR4 and 293-hTLR4-CD14/MD2 cells were purchased from InvivoGen and maintained in 10% DMEM supplemented with 10ug/mL blasticidin (293-hTLR4) or 10ug/mL blasticidin and 50ug/mL HygroGold (293-hTLR4-CD14/MD2). HSV-2 strain 333 was grown and titred as previously described [49]. VSV expressing GFP was kindly provided by Dr. Brian Lichty (McMaster University, Hamilton, ON). GM-CSF was purchased from R&D. alpha-D-manosidase, LPS (L26-54) and Poly I:C were purchased from Sigma (Oakville, ON, Canada). Depo-Provera was purchased from Upjohn (Don Mills, ON, Canada).
###end p 47
###begin title 48
Purification of FimH
###end title 48
###begin p 49
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fimH</italic>
###xml 36 43 36 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 118 125 118 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 199 203 199 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Kariyawasam1">[50]</xref>
###xml 36 43 <span type="species:ncbi:562">E. coli</span>
###xml 118 125 <span type="species:ncbi:562">E. coli</span>
The fimH gene from avian pathogenic E. coli strain EC99 (O78) was cloned into pQE-30 and expressed in BL-21 competent E. coli. FimH expression and purification were performed as previously described [50]. Briefly, Protein expression was induced by adding 1M IPTG to a final concentration of 1 mM and induction continued for a period of 5 hours. Bacterial pellets were lysed and protein isolation continued under denaturing conditions utilizing Ni-NTA affinity chromatography. Isolated protein fractions were then dialyzed in a 10-kDa Slidlyzer dialysis cassette against PBS. The LPS contraction in the purified FimH protein was determined using Limulus Amebocyte Lysate LPS detection kit according to the manufacturer's protocol.
###end p 49
###begin title 50
Treatment of RAW264.7 cells and MEFs with ligands
###end title 50
###begin p 51
###xml 409 412 395 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 419 422 405 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 428 431 414 417 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 450 453 429 432 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 454 458 <span type="species:ncbi:10090">mice</span>
RAW264.7 cells were treated with FimH (10 microg/ml), Poly I:C (10 microg/ml) or left un-treated. Twenty-four hours post treatment the supernatants were collected and stored at -20degreesC for further study. The cells were then infected with HSV-2, MOI of 0.1. Twenty to twenty-two hours post infection the cells and supernatants were collected for HSV-2 titration on Vero cells. Passage 3 MEFs from B6, IRF-3-/-, MyD88-/-, Trif-/- and IFNalpha/betaR-/- mice were split into 12-well plates and then treated with various concentrations of FimH, Poly I:C or LPS or left un-treated. Twenty-four hours post treatment, MEFs were infected with VSV-GFP. Levels of GFP fluorescence were visualized and quantified using a Typhoontrade mark scanner (GE Healthcare) 24 hours post-infection.
###end p 51
###begin title 52
Local delivery of TLR ligands, genital HSV-2 inoculation and vaginal virus titration
###end title 52
###begin p 53
###xml 8 11 8 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 17 20 17 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 27 30 27 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 49 52 42 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 740 744 717 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000233-Docherty1">[49]</xref>
###xml 53 57 <span type="species:ncbi:10090">mice</span>
###xml 134 139 <span type="species:ncbi:10090">mouse</span>
###xml 176 180 <span type="species:ncbi:10090">mice</span>
###xml 243 248 <span type="species:ncbi:10090">mouse</span>
###xml 274 279 <span type="species:ncbi:10090">mouse</span>
###xml 320 324 <span type="species:ncbi:10090">mice</span>
###xml 754 758 <span type="species:ncbi:10090">mice</span>
###xml 1226 1230 <span type="species:ncbi:10090">mice</span>
B6, TLR4-/-,IRF-3-/-, MyD88-/- and IFNalpha/betaR-/- mice, 6-8 weeks old, were subcutaneously (sc) injected with 2 mg of progesterone/mouse (Depo-Provera). Four days later the mice were anaesthetized and treated vaginally with FimH (40 microg/mouse) or Poly I:C (100 microg/mouse). Twenty-four hours after treatment the mice were anesthetised, placed on their backs, and infected IVAG with a lethal dose of HSV-2 in 10 microl of PBS for at least 45 min while being maintained under anaesthesia. Vaginal washes were collected daily after infection (days 1-3) by pipetting 2x30 microL of PBS into and out of the vagina 6-8 times. Viral titers in IVAG washes were determined by plaque assay on monolayers of Vero cells as previously described [49]. Treated mice were also monitored daily for genital pathology and survival for up to 4 weeks. Pathology was scored on a five point scale. Zero indicated no infection; 1, slight redness of external vagina; 2, swelling and redness of external vagina; 3, severe swelling of external vagina and hair loss in the surrounding area; 4, ulceration of vaginal tissue, redness and swelling; 5, continued ulceration, redness, swelling and sometimes paralysis in back legs, at which point the mice were euthanized.
###end p 53
###begin title 54
Histomorphology of the genital tract
###end title 54
###begin p 55
###xml 87 91 <span type="species:ncbi:10090">mice</span>
###xml 117 122 <span type="species:ncbi:10090">mouse</span>
###xml 141 146 <span type="species:ncbi:10090">mouse</span>
To study the effects of FimH or LPS on vaginal tissue morphology, progesterone-treated mice received FimH (40 microg/mouse) or LPS (5 microg/mouse). After 24 h, vaginal tissue was removed, fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned at 5 microm for hematoxylin and eosin staining.
###end p 55
###begin title 56
ELISA for IFN-alpha, IFN-beta, TNF-alpha, IFN-gamma and IL-8
###end title 56
###begin p 57
###xml 79 85 <span type="species:ncbi:10090">Murine</span>
###xml 312 317 <span type="species:ncbi:10090">mouse</span>
IFN-alpha, IFN-beta, IFN-gamma and IL-8 ELISAs were conducted using Quantikine Murine Kits from R&D Systems (Minneapolis, MN, USA) according to the manufacturer's instructions. IFN-alpha and IFN-beta ELISAs were conducted using PBL Biomedical kits from PBL (Piscataway, NJ, USA). The IFN-alpha ELISA kit detects mouse IFN-alphaA, IFN-alpha1, IFN-alpha4, IFN-alpha5, IFN-alpha6, and IFN-alpha9, with a detection limit of 10 pg/ml.
###end p 57
###begin title 58
Bacteria and experimental urinary tract infection
###end title 58
###begin p 59
###xml 42 58 42 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 118 125 118 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 189 193 189 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fimH</italic>
###xml 204 211 204 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 348 355 348 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 576 577 560 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sup>
###xml 629 632 613 616 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 662 663 646 647 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 2 7 <span type="species:ncbi:9606">human</span>
###xml 42 58 <span type="species:ncbi:562">Escherichia coli</span>
###xml 112 116 <span type="species:ncbi:10090">mice</span>
###xml 118 130 <span type="species:ncbi:569579">E. coli NU14</span>
###xml 204 216 <span type="species:ncbi:569579">E. coli NU14</span>
###xml 348 355 <span type="species:ncbi:562">E. coli</span>
###xml 421 426 <span type="species:ncbi:10090">mouse</span>
###xml 616 620 <span type="species:ncbi:10090">mice</span>
###xml 758 762 <span type="species:ncbi:10090">mice</span>
A human cystitis isolate of uropathogenic Escherichia coli was used for experimental urinary tract infection of mice. E. coli NU14-1, which does not express FimH due to a disruption of the fimH gene, and E. coli NU14, which is the isogenic wild type parent strain, were kindly provided by Dr. Scott Hultgren (Washington University, St. Louis, MO). E. coli were cultured in LB broth with streptomycin at 50 microg ml. For mouse infection studies, bacteria were grown overnight in LB broth, washed in 0.85% saline, and resuspended in saline to a concentration of approximately109 colony forming units (cfu) per ml. B6 mice and TLR4-/- were infected with 0.1 ml (108 cfu) of bacterial suspension. A soft catheter (0.7 mm) placed in the urethra of anaesthetized mice and the bacterial were delivered into balder. Urine was collected 0, 2, 6 and 24 hours post-infection and polymorphonuclear leukocytes were quantified using a haemocytometer. Twenty-four hours after infection, the bladders were removed, homogenized and the bacterial load was enumerated.
###end p 59
###begin title 60
Statistical analysis
###end title 60
###begin p 61
###xml 234 235 232 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 244 245 242 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 315 316 313 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Statistical differences among the viral titers were determined by analysis of variance followed by Tukey's test. The statistical significances of the survival rates and the percentage of GFP expressing cells were determined by the chi2 test. A P value of <0.05 was considered statistically significant. An unpaired t test was used to determine significant differences in cytokine production.
###end p 61
###begin title 62
Supporting Information
###end title 62
###begin p 63
Supplementary Data
###end p 63
###begin p 64
(4.22 MB TIF)
###end p 64
###begin p 65
Click here for additional data file.
###end p 65
###begin p 66
###xml 102 105 95 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 183 186 176 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 263 266 256 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 320 323 313 316 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 469 470 462 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 479 480 472 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
###xml 187 191 <span type="species:ncbi:10090">mice</span>
###xml 267 271 <span type="species:ncbi:10090">mice</span>
###xml 324 328 <span type="species:ncbi:10090">mice</span>
###xml 481 485 <span type="species:ncbi:562">UPEC</span>
We thank Drs. Rolf M. Zinkernagle and Ken L. Rosenthal for providing breeding pairs of IFN-alpha/betaR-/- mice, Dr. Tadatsugu Taniguchi via Dr. Thomas Moran for breeding pairs of IRF3-/- mice, Dr. Shizuo Akira via Dr. Douglas Golenbock for breeding pairs of MyD88-/- mice and Dr. Bruce Beutler for breeding pairs of Trif-/- mice. We also thank Drs. Brian Lichty for VSV expressing GFP and Scott Hultgren (Washington University, St. Louis, MO) for providing us with FimH+ and FimH- UPEC.
###end p 66
###begin title 67
References
###end title 67
###begin article-title 68
Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections.
###end article-title 68
###begin article-title 69
Interferons alpha and beta as immune regulators-a new look.
###end article-title 69
###begin article-title 70
###xml 132 159 <span type="species:ncbi:10310">herpes simplex virus type 2</span>
Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2.
###end article-title 70
###begin article-title 71
###xml 19 46 <span type="species:ncbi:10310">herpes simplex virus type 2</span>
Innate immunity to herpes simplex virus type 2.
###end article-title 71
###begin article-title 72
Up-regulation of NK cytotoxic activity via IL-15 induction by different viruses: a comparative study.
###end article-title 72
###begin article-title 73
Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin).
###end article-title 73
###begin article-title 74
Toll-like receptors: critical proteins linking innate and acquired immunity.
###end article-title 74
###begin article-title 75
Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.
###end article-title 75
###begin article-title 76
Innate immunity.
###end article-title 76
###begin article-title 77
Innate immunity: the virtues of a nonclonal system of recognition.
###end article-title 77
###begin article-title 78
Introduction: the role of innate immunity in the adaptive immune response.
###end article-title 78
###begin article-title 79
###xml 39 59 <span type="species:ncbi:139">Borrelia burgdorferi</span>
###xml 68 74 <span type="species:ncbi:9606">humans</span>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice.
###end article-title 79
###begin article-title 80
Toll-like receptor 9, CpG DNA and innate immunity.
###end article-title 80
###begin article-title 81
###xml 34 39 <span type="species:ncbi:9606">human</span>
Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells.
###end article-title 81
###begin article-title 82
TLR11 Activation of Dendritic Cells by a Protozoan Profilin-Like Protein.
###end article-title 82
###begin article-title 83
A toll-like receptor that prevents infection by uropathogenic bacteria.
###end article-title 83
###begin article-title 84
Recognition of pathogen-associated molecular patterns by TLR family.
###end article-title 84
###begin article-title 85
###xml 105 109 <span type="species:ncbi:10090">mice</span>
Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice.
###end article-title 85
###begin article-title 86
Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA.
###end article-title 86
###begin article-title 87
###xml 90 95 <span type="species:ncbi:10090">mouse</span>
A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection.
###end article-title 87
###begin article-title 88
###xml 93 120 <span type="species:ncbi:10310">herpes simplex virus type 2</span>
Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection.
###end article-title 88
###begin article-title 89
Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge.
###end article-title 89
###begin article-title 90
Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4.
###end article-title 90
###begin article-title 91
A crucial role for plasmacytoid dendritic cells in antiviral protection by CpG ODN-based vaginal microbicide.
###end article-title 91
###begin article-title 92
Adhesins as targets for vaccine development.
###end article-title 92
###begin article-title 93
###xml 36 52 <span type="species:ncbi:562">Escherichia coli</span>
Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract.
###end article-title 93
###begin article-title 94
###xml 44 60 <span type="species:ncbi:562">Escherichia coli</span>
Identification of two ancillary subunits of Escherichia coli type 1 fimbriae by using antibodies against synthetic oligopeptides of fim gene products.
###end article-title 94
###begin article-title 95
###xml 95 103 <span type="species:ncbi:9031">chickens</span>
###xml 129 145 <span type="species:ncbi:562">Escherichia coli</span>
Immunization with the binding domain of FimH, the adhesin of type 1 fimbriae, does not protect chickens against avian pathogenic Escherichia coli.
###end article-title 95
###begin article-title 96
###xml 42 58 <span type="species:ncbi:562">Escherichia coli</span>
###xml 116 121 <span type="species:ncbi:9606">women</span>
Fimch antiserum inhibits the adherence of Escherichia coli to cells collected by voided urine specimens of diabetic women.
###end article-title 96
###begin article-title 97
[Candidate vaccine against urinary tract infections].
###end article-title 97
###begin article-title 98
PapD-like chaperones provide the missing information for folding of pilin proteins.
###end article-title 98
###begin article-title 99
Systemic immunization with conserved pilus-associated adhesins protects against mucosal infections.
###end article-title 99
###begin article-title 100
###xml 22 38 <span type="species:ncbi:562">Escherichia coli</span>
Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination.
###end article-title 100
###begin article-title 101
Type 1 pilus-mediated bacterial invasion of bladder epithelial cells.
###end article-title 101
###begin article-title 102
###xml 25 41 <span type="species:ncbi:562">Escherichia coli</span>
Pathogenic adaptation of Escherichia coli by natural variation of the FimH adhesin.
###end article-title 102
###begin article-title 103
FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the Enterobacteriaceae.
###end article-title 103
###begin article-title 104
FimH adhesin of type 1 fimbriae is a novel TLR4 ligand
###end article-title 104
###begin article-title 105
###xml 22 38 <span type="species:ncbi:562">Escherichia coli</span>
###xml 70 76 <span type="species:ncbi:9913">bovine</span>
Adherent and invasive Escherichia coli are associated with persistent bovine mastitis.
###end article-title 105
###begin article-title 106
###xml 53 92 <span type="species:ncbi:149539">Salmonella enterica serovar Enteritidis</span>
Functional characterization of the FimH adhesin from Salmonella enterica serovar Enteritidis.
###end article-title 106
###begin article-title 107
###xml 55 71 <span type="species:ncbi:562">Escherichia coli</span>
Inhibition of the type 1 fimbriae-mediated adhesion of Escherichia coli to erythrocytes by multiantennary alpha-mannosyl clusters: the effect of multivalency.
###end article-title 107
###begin article-title 108
Novel Zn(2+)-chelating peptides selected from a fimbria-displayed random peptide library.
###end article-title 108
###begin article-title 109
BCL10 mediates lipopolysaccharide/toll-like receptor-4 signaling through interaction with Pellino2.
###end article-title 109
###begin article-title 110
Nitric oxide and macrophage antiviral extrinsic activity.
###end article-title 110
###begin article-title 111
###xml 49 53 <span type="species:ncbi:10090">mice</span>
Nitric oxide and HSV vaginal infection in BALB/c mice.
###end article-title 111
###begin article-title 112
Initial and innate responses to viral infections-pattern setting in immunity or disease.
###end article-title 112
###begin article-title 113
Immunostimulatory CpG treatment for genital HSV-2 infections.
###end article-title 113
###begin article-title 114
###xml 37 64 <span type="species:ncbi:10310">herpes simplex virus type 2</span>
Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production.
###end article-title 114
###begin article-title 115
Mechanism of pathogen-specific TLR4 activation in the mucosa: fimbriae, recognition receptors and adaptor protein selection.
###end article-title 115
###begin article-title 116
###xml 77 80 <span type="species:ncbi:9606">men</span>
Incidence of herpes simplex virus types 1 and 2 in penile lesions of college men.
###end article-title 116
###begin article-title 117
###xml 22 30 <span type="species:ncbi:9031">chickens</span>
###xml 34 50 <span type="species:ncbi:562">Escherichia coli</span>
Resistance of broiler chickens to Escherichia coli respiratory tract infection induced by passively transferred egg-yolk antibodies.
###end article-title 117
###begin p 118
We have filed a patent for the use of FimH as an innate microbicide.
###end p 118
###begin p 119
###xml 111 119 <span type="species:ncbi:9606">Children</span>
This work was supported by grants from Canadian Institutes of Health Research (CIHR) and the Hospital for Sick Children Foundation to Ali A. Ashkar. AAA and KLM are recipients of a Career Award in Health Sciences from Rx&D/CIHR. BKC is a recipient of New Investigator Award from CIHR and an Early Research Award from the Ministry of Research and Innovation of Ontario.
###end p 119

